RION

Focus: RION is a publicly traded biotechnology company headquartered in Rochester, MN, focused on exosome therapeutics with pipeline programs spanning cardiovascular, orthopedic, and wound care indications. The company operates at mid-cap scale with 201-500 employees.

Cardiovascular Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

201-500

Open Jobs

About RION

AI assessmentNot Hiring

No open roles listed right now. Follow RION to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PEP/Euflexxa

Knee Osteoarthritis

PHASE_1

Clinical Trials (1)

NCT06463132Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA)

Phase 1

Help build intelligence for RION

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering exosome platform with potential to establish new therapeutic modality across multiple indication areas
Public company status provides equity upside and career visibility while maintaining biotech innovation culture
Diversified pipeline with 5 active programs reduces single-asset dependency risk

Watch Out For

Pre-commercial stage with no approved products or revenue; early-phase pipeline (4 Phase 1, 1 Phase 2, zero Phase 3) means long runway to value realization
Only 1 active job opening signals minimal hiring momentum and limited near-term growth opportunities

Generated by Claude from RION's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PEP

Percutaneous Coronary Intervention

PHASE_1

Clinical Trials (1)

NCT04327635Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation

Phase 1

10% PEP

Skin Graft

PHASE_1

Clinical Trials (1)

NCT04664738PEP on a Skin Graft Donor Site Wound

Phase 1

PEP-TISSEEL

Chronic Radiation Ulcer

PHASE_1_2

Clinical Trials (1)

NCT06793748Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer

Phase 1/2

PEP

Diabetic Foot Ulcer

PHASE_2

Clinical Trials (1)

NCT06319287Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

1 pipeline

Marketed

Pipeline